Scinopharm Taiwan, Ltd.

As of June 30, 2026, Scinopharm Taiwan, Ltd. carries a market capitalization of 16.33B, placing it among publicly traded companies globally. Its enterprise value stands at 13.70B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Scinopharm Taiwan, Ltd.'s next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, Scinopharm Taiwan, Ltd. has 790.74M shares outstanding.

As of June 30, 2026, Scinopharm Taiwan, Ltd. trades at a trailing price-to-earnings ratio of 303.88. The price-to-sales ratio is 5.55, and the price-to-book ratio stands at 1.56.

As of June 30, 2026, Scinopharm Taiwan, Ltd. trades at an EV/EBITDA multiple of 25.01 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.43 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 436.72 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 13.70B versus a market cap of 16.33B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Scinopharm Taiwan, Ltd. maintains a current ratio of 4.74, meaning it holds 4.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 8.35, indicating elevated leverage, while an interest coverage ratio of 49.54 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Scinopharm Taiwan, Ltd. posted a return on equity (ROE) of 0.53, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 0.46, measuring how efficiently the asset base is converted into earnings. The company generates approximately 4.90M in revenue per employee across its workforce of 631.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.15 indicates how many times Scinopharm Taiwan, Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Scinopharm Taiwan, Ltd. recorded an income tax benefit of -20.01M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 36.48M, leaving 56.48M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Scinopharm Taiwan, Ltd.'s stock has gained approximately 5.42% over the past 52 weeks. The 50-day moving average sits at 19.00, while the 200-day moving average is 20.46.

Over the twelve months ended June 30, 2026, Scinopharm Taiwan, Ltd. generated 3.09B in revenue and converted that into 56.48M in net income, yielding earnings per share of 0.07. EBITDA reached 547.81M, while operating income came in at 47.60M.

As of June 30, 2026, Scinopharm Taiwan, Ltd. holds 3.50B in cash and equivalents against 873.09M in total debt, resulting in a net debt position of -3.31B. Total book value stands at 10.46B, with working capital of 4.60B providing operational flexibility.

Scinopharm Taiwan, Ltd. produced 830.72M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -244.97M in capital expenditures, free cash flow totaled 585.74M - equivalent to 0.70 per share.

Over the twelve months ended June 30, 2026, Scinopharm Taiwan, Ltd. posted a gross margin of 32.61, reflecting its pricing power and cost economics. The operating margin of 1.54 and net profit margin of 1.83 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Scinopharm Taiwan, Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 3.41, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.32, meaning Scinopharm Taiwan, Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Scinopharm Taiwan, Ltd.'s most recent stock split took place on August 10, 2017 with a 25:26 split ratio.

As of June 30, 2026, Scinopharm Taiwan, Ltd. has an Altman Z-Score of 5.89, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.